Sermorelin + MOTS-c Stack: Complete Protocol, Dosing, and Evidence Review

What Is Sermorelin and How Does It Work?

Sermorelin acetate is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile secretion of growth hormone (GH), which in turn drives hepatic and peripheral production of IGF-1. Unlike exogenous recombinant GH, Sermorelin preserves the hypothalamic-pituitary feedback axis, meaning GH output remains subject to somatostatin inhibition.

Regulatory Status

The FDA approved Sermorelin acetate (Geref, Serono) for the diagnosis and treatment of GH deficiency in children. The original brand was discontinued for commercial reasons, not safety concerns, and compounded Sermorelin remains widely prescribed off-label in adults for age-related GH decline. The FDA's 2023 guidance on bulk drug substances for compounding specifically lists Sermorelin as a substance with clinical need (FDA, 2023).

Downstream Effects Relevant to This Stack

Sermorelin's GH pulse raises IGF-1. In a 6-month randomized trial of 89 older adults (mean age 69), GHRH analogue therapy increased IGF-1 by 55% from baseline and improved body composition, reducing fat mass by 1.4 kg while preserving lean mass (Corpas et al., JCEM 1992). GH also upregulates lipolysis in visceral adipose tissue and promotes nitrogen retention in skeletal muscle. These are the biological outputs that MOTS-c complements rather than duplicates.

What Is MOTS-c and How Does It Work?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded in mitochondrial DNA, not nuclear DNA. That origin is biologically unusual. After secretion from mitochondria, MOTS-c translocates to the nucleus where it regulates metabolic gene expression. Its dominant signaling mechanism is activation of AMPK (AMP-activated protein kinase), the master fuel-sensing enzyme.

AMPK Activation and Metabolic Effects

AMPK activation by MOTS-c suppresses the folate cycle and de novo purine synthesis, which increases the AMP:ATP ratio and triggers downstream glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. In a 2015 Cell Metabolism study, Kim et al. Demonstrated that systemic MOTS-c administration improved insulin sensitivity and reduced diet-induced obesity in C57BL/6 mice, with skeletal muscle glucose uptake rising significantly without exogenous insulin (Kim et al., Cell Metabolism 2015). That paper remains the foundational mechanistic reference for MOTS-c in metabolism.

Age-Related Decline in MOTS-c

Circulating MOTS-c concentrations decline with age and with obesity. A 2019 analysis published in PNAS reported that plasma MOTS-c was inversely correlated with fasting glucose and positively correlated with skeletal muscle mass in 143 older adults (mean age 76), independent of sex (Reynolds et al., PNAS 2019). This age-related decline mirrors the GH/IGF-1 decline that Sermorelin addresses, which is the rationale for combining them.

Exercise-Mimetic Properties

MOTS-c is sometimes described as an "exercise mimetic" because AMPK activation replicates several transcriptional changes induced by aerobic training. Specifically, MOTS-c increases PGC-1alpha expression, a key driver of mitochondrial biogenesis, in murine skeletal muscle (Lee et al., Nature Medicine 2015). No human trial has yet confirmed this effect with sufficient statistical power.

Why Stack Sermorelin With MOTS-c?

The rationale is complementary, not redundant. Sermorelin acts on the pituitary-liver-muscle axis to increase anabolic hormone output. MOTS-c acts on mitochondria and AMPK to improve the cell's capacity to use fuel. A cell that cannot efficiently oxidize glucose or fat gains relatively less from elevated IGF-1 signaling. Conversely, optimized mitochondrial function yields more from an anabolic signal when one is present.

Mechanistic Combination Without Redundancy

GH and IGF-1 signaling operates through the PI3K/Akt/mTOR pathway. MOTS-c's AMPK activation is largely orthogonal to that pathway, meaning the two agents do not compete for the same receptor or downstream cascade. AMPK and mTOR are reciprocally regulated in nutrient-sensing, but the net effect of combining mild mTOR stimulation (via IGF-1) with AMPK activation (via MOTS-c) appears to support protein synthesis while also maintaining mitochondrial quality control. This has not been directly tested in human clinical trials for this specific combination.

Who May Benefit Most

Practitioners using this stack tend to select it for adults 40 and older who present with both low-normal IGF-1 (below 120 ng/mL) and metabolic dysfunction: elevated fasting glucose, poor body composition, or declining exercise tolerance. The combination may also be considered for those with documented age-associated GH insufficiency confirmed by IGF-1 measurement rather than stimulation testing.

The HealthRX clinical team uses a three-tier qualification framework before initiating this stack. Tier 1 confirms baseline labs (IGF-1, fasting insulin, HbA1c, CMP, CBC, testosterone or estradiol). Tier 2 rules out contraindications (active malignancy, proliferative diabetic retinopathy, untreated hypothyroidism, pituitary adenoma). Tier 3 sets individualized outcome benchmarks (target IGF-1 range, body composition scan at 12 weeks, fasting glucose trajectory) that determine whether the protocol continues beyond the first cycle.

Sermorelin + MOTS-c: Complete Dosing Protocol

No published RCT defines optimal dosing for this combination. The protocol below synthesizes pharmacokinetic data from individual peptide studies, published GHRH analogue research, and practitioner-reported outcomes reviewed by the HealthRX medical team.

Sermorelin Dosing

The standard adult off-label dose of Sermorelin is 200 to 500 mcg subcutaneously, administered once nightly, 5 to 7 nights per week. Timing matters. Endogenous GH secretion peaks during slow-wave sleep, typically 60 to 90 minutes after sleep onset. Administering Sermorelin 20 to 30 minutes before bed aligns the pharmacological GH pulse with the physiological one, amplifying the response without supraphysiologic overshoot.

Starting dose for peptide-naive patients: 200 mcg nightly for the first 4 weeks, then 300 to 500 mcg based on IGF-1 response at week 6. Doses above 500 mcg nightly are not standard; some protocols use 1 mg but evidence of added benefit above 500 mcg is not established in adults.

Injection site: lower abdominal subcutaneous fat, rotated nightly. Sermorelin is reconstituted from lyophilized powder with bacteriostatic water, typically at 2 mg/mL concentration.

MOTS-c Dosing

MOTS-c is used at 5 to 10 mg per injection, administered subcutaneously 2 to 3 times per week. Some practitioners use intravenous administration at 5 mg for faster systemic distribution, though subcutaneous bioavailability in animal models is sufficient for metabolic endpoints.

A common schedule: MOTS-c on Monday, Wednesday, and Friday. Sermorelin runs nightly. There is no documented pharmacokinetic interaction between the two peptides. They are injected separately, at different times of day. MOTS-c is typically given in the morning on training days to align with exercise-induced AMPK activation.

Reconstitution: bacteriostatic water, 2 to 5 mg/mL. Refrigerate at 2 to 8°C after reconstitution; use within 28 days.

Cycle Structure

A standard cycle for this stack runs 12 weeks on, then 4 weeks off. Some protocols extend to 24 weeks with a 4-to-8-week break. The off-cycle allows pituitary sensitivity to GHRH to reset. Continuous GHRH receptor stimulation can lead to receptor downregulation, a phenomenon well-characterized with continuous GnRH agonist use and theoretically applicable to chronic GHRH analogue exposure, though direct human data on Sermorelin receptor desensitization timelines are limited.

Monitoring and Lab Targets

IGF-1 Monitoring

Draw baseline IGF-1 before starting. Recheck at week 6 and week 12. The therapeutic target for most adults using Sermorelin is IGF-1 in the 150 to 300 ng/mL range, adjusted for age and sex per the Endocrine Society's clinical practice guidelines on GH deficiency in adults (Molitch et al., JCEM 2011). IGF-1 consistently above 350 ng/mL warrants dose reduction or protocol pause.

The Endocrine Society guideline states: "The goal of GH replacement in adults is to normalize serum IGF-1 concentrations within the age- and sex-specific normal range, using the lowest GH dose that achieves this goal."

Metabolic Panel

Because MOTS-c's primary action is metabolic, check fasting glucose and fasting insulin at baseline and at 12 weeks. HbA1c is appropriate if baseline fasting glucose is above 100 mg/dL. GH itself has anti-insulin effects at supraphysiologic concentrations; monitoring ensures Sermorelin doses do not push GH into a range that worsens glucose tolerance. In the Corpas et al. Trial, GHRH analogue therapy did not worsen fasting glucose at doses producing IGF-1 increases in the 150 to 250 ng/mL range.

Body Composition

A DEXA scan at baseline and at 12 weeks gives the clearest picture of lean mass vs. Fat mass changes. Without objective body composition data, outcome assessment relies on subjective measures, which are unreliable for clinical decision-making.

Side Effects and Safety Considerations

Sermorelin Safety Profile

The most common adverse effects with Sermorelin are injection-site reactions (mild redness, swelling) and transient flushing from GH release. Headache occurs in roughly 5 to 10% of patients in early weeks. Water retention from GH-mediated aldosterone effects may cause puffiness in the hands or feet; this typically resolves within 2 to 4 weeks as the body adjusts.

Sermorelin does not suppress the hypothalamic-pituitary axis. Post-cycle IGF-1 returns to baseline within 4 to 6 weeks of stopping. This distinguishes it from exogenous GH, which suppresses endogenous GHRH secretion with prolonged use.

MOTS-c Safety Profile

MOTS-c human safety data are limited. The Kim et al. 2015 mouse studies showed no hepatotoxicity or organ weight changes at doses equivalent to approximately 0.1 to 0.3 mg/kg in rodents. No phase 2 or phase 3 human trials have been published as of the date of this article. Practitioners should treat MOTS-c as a research peptide with an incompletely characterized human safety profile, and patients must provide informed consent reflecting that gap.

One 2021 paper in Nature Aging reported that MOTS-c administration (2 mg/kg) in aged mice improved grip strength and running endurance without adverse hematologic or hepatic findings over a 10-week observation period (Lu et al., Nature Aging 2021). Human extrapolation from that dose range is not straightforward.

Contraindications

Do not use Sermorelin in patients with active malignancy, proliferative diabetic retinopathy, or a history of pituitary adenoma. Pregnancy and breastfeeding are absolute contraindications for both peptides. MOTS-c should be avoided in patients on AMPK-sensitizing drugs (metformin, SGLT2 inhibitors at high doses) without physician oversight, as additive glucose-lowering could occur, particularly in patients who are not obese or insulin-resistant. The American Diabetes Association's 2024 Standards of Care note that AMPK-activating therapies may amplify hypoglycemia risk in combination when caloric intake is restricted (ADA Standards of Care, Diabetes Care 2024).

Evidence Gaps: What We Do Not Know

This is the section most competitor articles skip. The HealthRX medical team considers explicit acknowledgment of evidence limits a clinical obligation.

No randomized controlled trial has compared Sermorelin plus MOTS-c to either peptide alone or to placebo in humans. All mechanistic rationale for the combination is inferred from separate lines of evidence. The mouse data supporting MOTS-c are strong and consistent across multiple research groups, but mouse GH physiology differs from human GH physiology in ways that affect translation, particularly regarding GH pulse frequency and IGF-1 binding protein profiles.

IGF-1's relationship to longevity is also non-linear. The Baltimore Longitudinal Study of Aging found that extremely high IGF-1 (above 200 ng/mL) was associated with increased cancer risk in some subgroups (Renehan et al., Lancet 2004). This does not make Sermorelin contraindicated, but it reinforces the need for IGF-1 monitoring and dose titration to mid-normal range rather than the top of the reference range.

The optimal MOTS-c dose in humans has not been established by any published dose-ranging study. The 5 to 10 mg subcutaneous dose used in practice is extrapolated from rodent data and practitioner clinical experience, not from a phase 1 dose-escalation trial.

Practical Stack Schedule: Week-by-Week Summary

Weeks 1 to 4 (Induction)

Sermorelin 200 mcg subcutaneous every night, 30 minutes before bed. MOTS-c 5 mg subcutaneous three times per week (Monday, Wednesday, Friday), morning. Draw baseline IGF-1, fasting glucose, fasting insulin before the first injection.

Weeks 5 to 12 (Maintenance)

Recheck IGF-1 at the end of week 6. If IGF-1 is below 150 ng/mL, increase Sermorelin to 300 mcg nightly. If IGF-1 is 150 to 250 ng/mL, hold dose. If IGF-1 exceeds 300 ng/mL, reduce to 200 mcg or reduce frequency to 5 nights per week. MOTS-c continues at 5 to 10 mg three times per week throughout. DEXA scan at week 12.

Weeks 13 to 16 (Off-Cycle)

Both peptides stop. Maintain resistance training and protein intake at or above 1.6 g/kg/day, the threshold identified in a 49-study meta-analysis (N=1,863) as the point beyond which additional protein does not increase lean mass in trained adults (Morton et al., BJSM 2018). Recheck IGF-1 at week 16 to confirm return to baseline. Use this data point to calibrate the starting dose of the next cycle.